Rosa Bacchetta

List of Publications by Year
in descending order

109 papers	13,441 citations	28274 55 h-index	28297 105 g-index
111 all docs	111 docs citations	111 times ranked	15709 citing authors

#	Article	IF	Citations
1	Interleukinâ€10â€secreting type 1 regulatory T cells in rodents and humans. Immunological Reviews, 2006, 212, 28-50.	6.0	1,071
2	Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nature Biotechnology, 2015, 33, 985-989.	17.5	882
3	Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. International Immunology, 2007, 19, 345-354.	4.0	756
4	Type 1 T regulatory cells. Immunological Reviews, 2001, 182, 68-79.	6.0	745
5	Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nature Medicine, 2013, 19, 739-746.	30.7	700
6	Reprogramming human T cell function and specificity with non-viral genome targeting. Nature, 2018, 559, 405-409.	27.8	630
7	Defective regulatory and effector T cell functions in patients with FOXP3 mutations. Journal of Clinical Investigation, 2006, 116, 1713-1722.	8.2	462
8	High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells.. Journal of Experimental Medicine, 1994, 179, 493-502.	8.5	393
9	The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. Journal of Clinical Investigation, 2005, 115, 3276-3284.	8.2	386
10	The Role of IL-10 and TGF-Î² in the Differentiation and Effector Function of T Regulatory Cells. International Archives of Allergy and Immunology, 2002, 129, 263-276.	2.1	351
11	From IPEX syndrome to <i>FOXP3</i> mutation: a lesson on immune dysregulation. Annals of the New York Academy of Sciences, 2018, 1417, 5-22.	3.8	289
12	Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome: A Paradigm of Immunodeficiency with Autoimmunity. Frontiers in Immunology, 2012, 3, 211.	4.8	279
13	Tr1 cells: From discovery to their clinical application. Seminars in Immunology, 2006, 18, 120-127.	5.6	246
14	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. Journal of Allergy and Clinical Immunology, 2018, 141, 1036-1049.e5.	2.9	233
15	The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases. Immunity, 2018, 49, 1004-1019.	14.3	230
16	Role of regulatory T cells and FOXP3 in human diseases. Journal of Allergy and Clinical Immunology, 2007, 120, 227-235.	2.9	228
17	CD4⁺ Tâ€regulatory cells: toward therapy for human diseases. Immunological Reviews, 2008, 223, 391-421.	6.0	213
18	Generation of Potent and Stable Human CD4+ T Regulatory Cells by Activation-independent Expression of FOXP3. Molecular Therapy, 2008, 16, 194-202.	8.2	206

#	Article	IF	Citations
19	Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: Inconsistent correlation between forkhead box protein 3 expression and disease severity. Journal of Allergy and Clinical Immunology, 2008, 122, 1105-1112.e1.	2.9	199
20	Tr1 Cells and the Counter-Regulation of Immunity: Natural Mechanisms and Therapeutic Applications. Current Topics in Microbiology and Immunology, 2014, 380, 39-68.	1.1	191
21	Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clinical Immunology, 2013, 146, 248-261.	3.2	186
22	Growth and expansion of human Tâ€žregulatory typeâ€ž1 cells are independent from TCR activation but require exogenous cytokines. European Journal of Immunology, 2002, 32, 2237.	2.9	180
23	CD4+ regulatory T cells: Mechanisms of induction and effector function. Autoimmunity Reviews, 2005, 4, 491-496.	5.8	167
24	STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25âˆ’ effector T cells. International Immunology, 2008, 20, 421-431.	4.0	166
25	Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood, 2013, 121, 1595-1603.	1.4	145
26	Human inborn errors of immunity: An expanding universe. Science Immunology, 2020, 5, .	11.9	138
27	Hurdles in therapy with regulatory T cells. Science Translational Medicine, 2015, 7, 304ps18.	12.4	136
28	Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. International Immunology, 1992, 4, 1389-1397.	4.0	131
29	CD4+ T Cells from IPEX Patients Convert into Functional and Stable Regulatory T Cells by FOXP3 Gene Transfer. Science Translational Medicine, 2013, 5, 215ra174.	12.4	129
30	Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. Frontiers in Immunology, 2014, 5, 16.	4.8	126
31	Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. European Journal of Immunology, 2011, 41, 1652-1662.	2.9	122
32	IL-21 signalling via STAT3 primes human naÃ¯ve B cells to respond to IL-2 to enhance their differentiation into plasmablasts. Blood, 2013, 122, 3940-3950.	1.4	121
33	Clinical Features and Follow-Up in Patients with 22q11.2 Deletion Syndrome. Journal of Pediatrics, 2014, 164, 1475-1480.e2.	1.8	119
34	Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency. Journal of Allergy and Clinical Immunology, 2018, 142, 1679-1695.	2.9	106
35	Identity and Diversity of Human Peripheral Th and T Regulatory Cells Defined by Single-Cell Mass Cytometry. Journal of Immunology, 2018, 200, 336-346.	0.8	89
36	Regulatory T cells and their roles in immune dysregulation and allergy. Immunologic Research, 2014, 58, 358-368.	2.9	87

#	Article	IF	Citations
37	Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1β inhibition. Journal of Allergy and Clinical Immunology, 2019, 144, 1122-1125.e6.	2.9	85
38	CRISPR-based gene editing enables *FOXP3* gene repair in IPEX patient cells. Science Advances, 2020, 6, eaaz0571.	10.3	84
39	Regulated and Multiple miRNA and siRNA Delivery Into Primary Cells by a Lentiviral Platform. Molecular Therapy, 2009, 17, 1039-1052.	8.2	83
40	Epigenetic immune cell counting in human blood samples for immunodiagnostics. Science Translational Medicine, 2018, 10, .	12.4	83
41	Host-reactive CD4+ and CD8+ T cell clones isolated from a human chimera produce IL-5, IL-2, IFN-gamma and granulocyte/macrophage-colony-stimulating factor but not IL-4. Journal of Immunology, 1990, 144, 902-8.	0.8	82
42	Selective engraftment of donor CD4+25high FOXP3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation. Blood, 2009, 113, 5689-5691.	1.4	75
43	Human hematopoietic cells and thymic epithelial cells induce tolerance via different mechanisms in the SCID-hu mouse thymus.. Journal of Experimental Medicine, 1992, 175, 1033-1043.	8.5	74
44	Congenital diarrhoeal disorders: advances in this evolving web of inherited enteropathies. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 293-302.	17.8	74
45	A novel function for FOXP3 in humans: intrinsic regulation of conventional T cells. Blood, 2013, 121, 1265-1275.	1.4	73
46	Functional type 1 regulatory T cells develop regardless of *FOXP3* mutations in patients with IPEX syndrome. European Journal of Immunology, 2011, 41, 1120-1131.	2.9	72
47	Antigen recognition by MHC-incompatible cells of a human mismatched chimera.. Journal of Experimental Medicine, 1988, 168, 2139-2152.	8.5	71
48	Clinical tolerance in allogeneic hematopoietic stem cell transplantation. Immunological Reviews, 2011, 241, 145-163.	6.0	68
49	Autoantibodies to Harmonin and Villin Are Diagnostic Markers in Children with IPEX Syndrome. PLoS ONE, 2013, 8, e78664.	2.5	68
50	Demethylation analysis of the FOXP3 locus shows quantitative defects of regulatory T cells in IPEX-like syndrome. Journal of Autoimmunity, 2012, 38, 49-58.	6.5	67
51	Identification of STAT5A and STAT5B Target Genes in Human T Cells. PLoS ONE, 2014, 9, e86790.	2.5	67
52	An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells. Journal of Experimental Medicine, 2005, 201, 1293-1305.	8.5	64
53	Molecular and functional characterization of alloantigen-specific anergic T cells suitable for cell therapy. Haematologica, 2010, 95, 2134-2143.	3.5	63
54	Natural killer cell clones can efficiently process and present protein antigens. Journal of Immunology, 1991, 147, 781-7.	0.8	62

#	Article	IF	Citations
55	Gene therapy for primary immunodeficiencies: Part 2. Current Opinion in Immunology, 2012, 24, 585-591.	5.5	61
56	Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. Haematologica, 2009, 94, 1415-1426.	3.5	57
57	Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Frontiers in Immunology, 2020, 11, 239.	4.8	57
58	Forkhead box protein 3 (FOXP3) mutations lead to increased TH17 cell numbers and regulatory T-cell instability. Journal of Allergy and Clinical Immunology, 2011, 128, 1376-1379.e1.	2.9	54
59	Wild-type FOXP3 is selectively active in CD4+CD25hi regulatory T cells of healthy female carriers of different FOXP3 mutations. Blood, 2009, 114, 4138-4141.	1.4	49
60	Clinical heterogeneity and diagnostic delay of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Clinical Immunology, 2011, 139, 6-11.	3.2	49
61	Point mutants of forkhead box P3 that cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked have diverse abilities to reprogram T cells into regulatory T cells. Journal of Allergy and Clinical Immunology, 2010, 126, 1242-1251.	2.9	48
62	Intergenerational and intrafamilial phenotypic variability in 22q11.2 Deletion syndrome subjects. BMC Medical Genetics, 2014, 15, 1.	2.1	48
63	Treatment with rapamycin can restore regulatory T-cell function in IPEX patients. Journal of Allergy and Clinical Immunology, 2020, 145, 1262-1271.e13.	2.9	48
64	Neutralizing Anti-Cytokine Autoantibodies Against Interferon-Î± in Immunodysregulation Polyendocrinopathy Enteropathy X-Linked. Frontiers in Immunology, 2018, 9, 544.	4.8	46
65	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology, 2017, 8, 1844.	4.8	43
66	Reappraisal of in utero Stem Cell Transplantation Based on Long-Term Results. Fetal Diagnosis and Therapy, 2004, 19, 305-312.	1.4	41
67	Differentiating the roles of STAT5B and STAT5A in human CD4+ T cells. Clinical Immunology, 2013, 148, 227-236.	3.2	40
68	Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. Science Translational Medicine, 2021, 13, eabf5264.	12.4	40
69	Chimerism and tolerance to host and donor in severe combined immunodeficiencies transplanted with fetal liver stem cells.. Journal of Clinical Investigation, 1993, 91, 1067-1078.	8.2	39
70	<i>Forkhead box P3:</i>The Peacekeeper of the Immune System. International Reviews of Immunology, 2014, 33, 129-145.	3.3	33
71	Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3. Blood, 2015, 125, 3886-3895.	1.4	33
72	Severe Toxoplasma gondii infection in a member of a NFKB2-deficient family with T and B cell dysfunction. Clinical Immunology, 2017, 183, 273-277.	3.2	32

#	Article	IF	Citations
73	Peanut-specific type 1 regulatory T cells induced inÂvitro from allergic subjects are functionally impaired. Journal of Allergy and Clinical Immunology, 2018, 141, 202-213.e8.	2.9	30
74	Humanâ€engineered Tregâ€like cells suppress FOXP3â€deficient T cells but preserve adaptive immune responses <i>in vivo</i>. Clinical and Translational Immunology, 2020, 9, e1214.	3.8	30
75	Methods for In Vitro Generation of Human Type 1 Regulatory T Cells. Methods in Molecular Biology, 2010, 677, 31-46.	0.9	29
76	Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetes. Clinical Immunology and Immunopathology, 1988, 49, 53-62.	2.0	26
77	Ectopic FOXP3 Expression Preserves Primitive Features Of Human Hematopoietic Stem Cells While Impairing Functional T Cell Differentiation. Scientific Reports, 2017, 7, 15820.	3.3	26
78	Forkhead-Box-P3 Gene Transfer in Human CD4+ T Conventional Cells for the Generation of Stable and Efficient Regulatory T Cells, Suitable for Immune Modulatory Therapy. Frontiers in Immunology, 2017, 8, 1282.	4.8	26
79	Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome. Frontiers in Immunology, 2019, 10, 753.	4.8	25
80	Human Ig production and isotype switching in severe combined immunodeficient-human mice. Journal of Immunology, 1993, 151, 128-37.	0.8	24
81	Combined DOCK8 and CLEC7A mutations causing immunodeficiency in 3 brothers with diarrhea, eczema, and infections. Journal of Allergy and Clinical Immunology, 2013, 131, 594-597.e3.	2.9	22
82	Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome. Current Gene Therapy, 2014, 14, 422-428.	2.0	19
83	Regulatory T cells: prospective for clinical application in hematopoietic stem cell transplantation. Current Opinion in Hematology, 2005, 12, 451-456.	2.5	18
84	Role of human forkhead box P3 in early thymic maturation and peripheral T-cell homeostasis. Journal of Allergy and Clinical Immunology, 2018, 142, 1909-1921.e9.	2.9	17
85	Towards gene therapy for IPEX syndrome. European Journal of Immunology, 2022, 52, 705-716.	2.9	16
86	Induction of transplantation tolerance in humans using fetal cell transplants. Transplantation Proceedings, 2005, 37, 65-66.	0.6	13
87	APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIRâ„¢) to Induce Antigen-Specific T Regulatory Type 1 Cells. Frontiers in Immunology, 2018, 9, 881.	4.8	13
88	Co-Expression of FOXP3FL and FOXP3Î"2 Isoforms Is Required for Optimal Treg-Like Cell Phenotypes and Suppressive Function. Frontiers in Immunology, 2021, 12, 752394.	4.8	13
89	Interleukin-10 Anergized Donor T Cell Infusion Improves Immune Reconstitution without Severe Graft-Versus-Host-Disease After Haploidentical Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 45-45.	1.4	12
90	The autoimmune targets in IPEX are dominated by gut epithelial proteins. Journal of Allergy and Clinical Immunology, 2019, 144, 327-330.e8.	2.9	11

#	Article	IF	Citations
91	BHLHE40 Regulates IL-10 and IFN-Î³ Production in T Cells but Does Not Interfere With Human Type 1 Regulatory T Cell Differentiation. Frontiers in Immunology, 2021, 12, 683680.	4.8	11
92	Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells. Haematologica, 2021, 106, 2588-2597.	3.5	11
93	Immunodeficiency with Autoimmunity: Beyond the Paradox. Frontiers in Immunology, 2013, 4, 77.	4.8	9
94	A SCID patient reconstituted with HLA-incompatible fetal stem cells as a model for studying transplantation tolerance. Nouvelle Revue FranÃ§aise D'hÃ©matologie, 1991, 17, 391-402.	0.7	9
95	T-Cell Subsets and Their Cytokine Profiles in Transplantation and Tolerance. Annals of the New York Academy of Sciences, 1995, 770, 141-148.	3.8	8
96	Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif. EMBO Journal, 1993, 12, 4375-84.	7.8	8
97	Utilizing regulatory T cells to control alloreactivity. Cytotherapy, 2005, 7, 158-165.	0.7	7
98	Immunological lessons learnt from patients transplanted with fully mismatched stem cells. Immunologic Research, 2007, 38, 201-209.	2.9	7
99	Thymic origins of autoimmunityâ€"lessons from inborn errors of immunity. Seminars in Immunopathology, 2021, 43, 65-83.	6.1	7
100	Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy. Cytotherapy, 2021, 23, 1017-1028.	0.7	5
101	Clinical improvement and normalized Th1 cytokine profile in early and long-term interferon-Î± treatment in a suspected case of hyper-IgE syndrome. Pediatric Allergy and Immunology, 2008, 19, 564-568.	2.6	4
102	Design of experiments as a decision tool for cell therapy manufacturing. Cytotherapy, 2022, 24, 590-596.	0.7	3
103	In Vitro Induction of Peanut-Specific Tr1 Cells. Journal of Allergy and Clinical Immunology, 2016, 137, AB407.	2.9	2
104	Type 1 Diabetes Mellitus in Monogenic Autoimmune Diseases. Frontiers in Diabetes, 2017, , 78-90.	0.4	2
105	Regulatory Type 1 T Cell Infusion in Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, S272-S273.	2.0	2
106	Congenital Immunodeficiency Diseases. , 2016, , 45-81.		0
107	Immunodysregulation, Polyendocrinopathy, and Enteropathy, X-Linked (IPEX) Syndrome. , 2016, , 444-450.		0
108	146â€¦Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1. , 2020, , .		0

#	Article	IF	Citations
109	Editorial: IPEX 2020: An Expanding Disease Spectrum and Novel Precision Therapies. Frontiers in Pediatrics, 2022, 10, 856920.	1.9	0